NOVABRIDGE BIOSCIENCES (NASDAQ: NBP)

NOVABRIDGE BIOSCIENCES

NASDAQ: NBP (NovaBridge Biosciences)

Kemas kini terakhir: 2 hari lalu, 6:20AM

3.99

0.14 (3.64%)

Tambah ke senarai pantauan

Penutupan Terdahulu	3.85
Buka	3.85
Jumlah Dagangan	516,023
Purata Dagangan (3B)	1,337,253
Modal Pasaran	459,911,552

Harga / Jualan (P/S)	25.39
Harga / Buku (P/B)	2.25

Julat 52 Minggu	0.595 (-85%) — 6.79 (70%)
Tarikh Pendapatan	5 Dec 2025

Arah Aliran Pasaran

		Jangka Pendek	Jangka Sederhana
Industri	Biotechnology (US)	Menaik	Bercampur
	Biotechnology (Global)	Menaik	Bercampur
Stok	NovaBridge Biosciences	-	-

AISkor Stockmoo

0.1

Konsensus Penganalisis	2.0
Aktiviti Orang Dalam	NA
Volatiliti Harga	-4.5
Purata Bergerak Teknikal	3.5
Osilator Teknikal	-0.5
Purata	0.13

Saham Serupa

Stok	Modal Pasaran	DY	P/E (TTM)	P/B
NBP	460 M	-	-	2.25
LEGN	5 B	-	-	5.06
MAZE	2 B	-	-	4.82
DNTH	2 B	-	-	3.45
ELVN	1 B	-	-	2.56
JBIO	570 M	-	-	-

NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.
Sektor	Healthcare
Industri	Biotechnology

Pemilikan

Nama	Tarikh	Syer Dipegang
Ariose Capital Management Ltd	30 Sep 2025	1,704,393
Exome Asset Management Llc	30 Sep 2025	1,439,604
Edbi Pte Ltd	31 Dec 2024	222,136

Tiada data dalam julat masa ini.

Tarikh	Jenis	Butiran
03 Dec 2025	Pengumuman	NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
20 Nov 2025	Pengumuman	NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
29 Oct 2025	Pengumuman	I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
22 Oct 2025	Pengumuman	I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025
16 Oct 2025	Pengumuman	I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
15 Oct 2025	Pengumuman	Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge
14 Oct 2025	Pengumuman	I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
07 Oct 2025	Pengumuman	Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
08 Sep 2025	Pengumuman	I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

Log masuk untuk menambahkan ke senarai pantauan

AI Templat

Peringatan harga anda

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Log masuk untuk menambahkan ke senarai pantauan

Keuntungan Nyata	-
Keuntungan Tidak Nyata	-
Dividen Diterima 2025	-
Jumlah Untung	-
Pulangan Purata	-
Kuantiti (Beli)	-
Purata Harga (Beli)	-
Kuantiti (Jual)	-
Purata Harga (Jual)	-

Log masuk untuk menambahkan ke senarai pantauan

Tiada saham yang memenuhi kriteria anda

Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)